BioMarin enters agreement to acquire Inozyme Pharma for $270 million
BioMarin Pharmaceutical Inc. and Inozyme Pharma, Inc. announced that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transaction for a total consideration of approximately $270 million. The transaction …